MACK vs. RIGL, EBS, XOMA, VSTM, RGLS, VNDA, LXRX, GTHX, RENB, and ATOS
Should you be buying Merrimack Pharmaceuticals stock or one of its competitors? The main competitors of Merrimack Pharmaceuticals include Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), XOMA (XOMA), Verastem (VSTM), Regulus Therapeutics (RGLS), Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), G1 Therapeutics (GTHX), Renovaro (RENB), and Atossa Therapeutics (ATOS). These companies are all part of the "pharmaceutical preparations" industry.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Merrimack Pharmaceuticals (NASDAQ:MACK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment.
66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.0% of Merrimack Pharmaceuticals shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 28.9% of Merrimack Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Rigel Pharmaceuticals presently has a consensus target price of $5.81, suggesting a potential upside of 511.58%. Given Merrimack Pharmaceuticals' higher possible upside, equities analysts plainly believe Rigel Pharmaceuticals is more favorable than Merrimack Pharmaceuticals.
Rigel Pharmaceuticals received 51 more outperform votes than Merrimack Pharmaceuticals when rated by MarketBeat users. Likewise, 68.85% of users gave Rigel Pharmaceuticals an outperform vote while only 66.89% of users gave Merrimack Pharmaceuticals an outperform vote.
Rigel Pharmaceuticals has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Merrimack Pharmaceuticals has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.
Merrimack Pharmaceuticals has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Merrimack Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Merrimack Pharmaceuticals. MarketBeat recorded 8 mentions for Rigel Pharmaceuticals and 6 mentions for Merrimack Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.95 beat Merrimack Pharmaceuticals' score of 0.51 indicating that Merrimack Pharmaceuticals is being referred to more favorably in the news media.
Merrimack Pharmaceuticals has a net margin of 0.00% compared to Merrimack Pharmaceuticals' net margin of -16.45%. Merrimack Pharmaceuticals' return on equity of 0.00% beat Rigel Pharmaceuticals' return on equity.
Summary
Rigel Pharmaceuticals and Merrimack Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Merrimack Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Merrimack Pharmaceuticals Competitors List
Related Companies and Tools
